BioPort Anthrax Vaccine Cost To DoD Could Increase, CEO Says
Executive Summary
BioPort's price to the Department of Defense for its anthrax vaccine is likely to increase from the current price of about $11, BioPort CEO Robert Kramer told a Senate Appropriations/HHS Subcommittee hearing Oct. 23.
You may also be interested in...
BioPort Anthrax Vaccine Production Could Begin Nov. 15 - HHS' Thompson
BioPort could begin production of anthrax vaccine by Nov. 15 if its Lansing, Mich. facility receives FDA approval, HHS Secretary Tommy Thompson told the Senate Governmental Affairs Committee Oct. 17.
BioPort
Department of Defense renegotiates contract with Lansing, Mich.-based anthrax vaccine manufacturer BioPort, agreeing to pay $10.64 per dose, up from the previous $4.36 per dose (1"The Pink Sheet" July 26, p. 28). BioPort will also manufacture fewer doses, down to 5.3 mil. from 7.6 mil. The value of the new contract, which runs through 2005, is $49.8 mil., compared to $25.7 mil. under the old contract. In addition, DoD has agreed to make an advance payment of $18.7 mil. to the company so that it can pay its creditors
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011